General Toxicity Notes
Myelosuppressive and may aggravate uremic predisposition to hemorrhage and infection.
Excreted Unchanged %
No data
Half-Life (Normalesrd) Hours
1/No data
Plasma Protein Binding %
No data
Volume Of Distribution L/Kg
0.86
Dose For Normal Renal Function
0.1 mg/kg q24h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
75% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
50% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: Dose for GFR <10, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: No data
References
Black DJ, Livingston RB. Antineoplastic drugs in 1990. A review (Part I). Drugs. 1990; 39: 489-501. [PMID: 2190792]